-
The parasite cytokine mimic Hp-TGM potently replicates the regulatory effects of TGF-β on murine CD4+ T cells.
Immunol Cell BiolWhite MPJ, Smyth DJ, Cook L, Ziegler SF, Levings MK, Maizels RM -
Induction of stable human FOXP3+ Tregs by a parasite-derived TGF-β mimic.
Immunol Cell BiolCook L, Reid KT, Häkkinen E, de Bie B, Tanaka S, Smyth DJ, White MP, Wong MQ, Huang Q, Gillies JK, Ziegler SF, Maizels RM, Levings MK -
Overview of oral tolerance induction for prevention of food allergy-Where are we now?
AllergyKrawiec M, Fisher HR, Du Toit G, Bahnson HT, Lack G -
Evolution of epitope-specific IgE and IgG4 antibodies in children enrolled in the LEAP trial.
J Allergy Clin ImmunolSuarez-Farinas M, Suprun M, Bahnson HT, Raghunathan R, Getts R, duToit G, Lack G, Sampson HA -
Thymic stromal lymphopoietin, skin barrier dysfunction, and the atopic march.
Ann Allergy Asthma ImmunolZiegler SF -
Targeting Versican as a Potential Immunotherapeutic Strategy in the Treatment of Cancer.
Front OncolHirani P, Gauthier V, Allen CE, Wight TN, Pearce OMT -
The Cyclin-Dependent Kinase 8 (CDK8) Inhibitor DCA Promotes a Tolerogenic Chemical Immunophenotype in CD4+ T Cells via a Novel CDK8-GATA3-FOXP3 Pathway.
Mol Cell BiolArnett A, Moo KG, Flynn KJ, Sundberg TB, Johannessen L, Shamji AF, Gray NS, Decker T, Zheng Y, Gersuk VH, Rahman ZS, Levy DE, Marié IJ, Linsley PS, Xavier RJ, Khor B -
Signals governing monocyte differentiation during inflammation.
Curr Opin ImmunolOrozco SL, Canny SP, Hamerman JA -
Tonic interferon restricts pathogenic IL-17-driven inflammatory disease via balancing the microbiome.
ElifeMarié IJ, Brambilla L, Azzouz D, Chen Z, Baracho GV, Arnett A, Li HS, Liu W, Cimmino L, Chattopadhyay P, Silverman G, Watowich SS, Khor B, Levy DE -
Immunophenotyping assessment in a COVID-19 cohort (IMPACC): A prospective longitudinal study
Sci ImmunolIMPACC Manuscript Writing Team -
Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy.
ElifeBarone SM, Paul AG, Muehling LM, Lannigan JA, Kwok WW, Turner RB, Woodfolk JA, Irish JM -
Endomembrane targeting of human OAS1 p46 augments antiviral activity.
ElifeSoveg FW, Schwerk J, Gokhale NS, Cerosaletti K, Smith JR, Pairo-Castineira E, Kell AM, Forero A, Zaver SA, Esser-Nobis K, Roby JA, Hsiang TY, Ozarkar S, Clingan JM, McAnarney ET, Stone AE, Malhotra U, Speake C, Perez J, Balu C, Allenspach EJ, Hyde JL, Menachery VD, Sarkar SN, Woodward JJ, Stetson DB, Baillie JK, Buckner JH, Gale M Jr, Savan R -
Biomarker technologies to support early clinical immuno-oncology development: Advances and interpretation
Clin Cancer ResCannarile MA, Gomes B, Canamero M, Reis B, Byrd AL, Charo J, Yadav M, Karanikas V -
Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Diabetes EndocrinolGitelman SE, Bundy BN, Ferrannini E, Lim N, Blanchfield JL, DiMeglio LA, Felner EI, Gaglia JL, Gottlieb PA, Long SA, Mari A, Mirmira RG, Raskin P, Sanda S, Tsalikian E, Wentworth JM, Willi SM, Krischer JP, Bluestone JA, Gleevec Trial Study Group. -
Immunotherapy: Building a bridge to a cure for type 1 diabetes.
ScienceBluestone JA, Buckner JH, Herold KC
